William Blair Has Pessimistic Outlook of LENZ Q1 Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Stock analysts at William Blair reduced their Q1 2025 earnings estimates for LENZ Therapeutics in a research report issued on Thursday, March 20th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings of ($0.56) per share for the quarter, down from their prior forecast of ($0.48). The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. William Blair also issued estimates for LENZ Therapeutics’ Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($2.97) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.77) EPS, Q3 2026 earnings at ($0.67) EPS and Q4 2026 earnings at ($0.53) EPS.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04).

Other equities analysts have also issued reports about the stock. TD Cowen assumed coverage on shares of LENZ Therapeutics in a report on Tuesday, March 18th. They set a “buy” rating and a $60.00 target price for the company. Citigroup raised their price target on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the company a “buy” rating in a research report on Thursday, March 20th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $41.67.

LENZ Therapeutics Trading Down 0.9 %

Shares of LENZ stock opened at $26.43 on Monday. LENZ Therapeutics has a twelve month low of $14.42 and a twelve month high of $38.93. The stock has a 50 day moving average of $24.30 and a 200 day moving average of $27.12. The stock has a market cap of $726.85 million, a P/E ratio of -5.54 and a beta of 0.58.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of LENZ Therapeutics during the fourth quarter valued at approximately $29,000. KLP Kapitalforvaltning AS acquired a new position in LENZ Therapeutics in the 4th quarter valued at $46,000. Tower Research Capital LLC TRC lifted its holdings in LENZ Therapeutics by 162.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company’s stock valued at $54,000 after purchasing an additional 1,151 shares in the last quarter. Virtus ETF Advisers LLC acquired a new stake in LENZ Therapeutics during the 4th quarter worth $67,000. Finally, SG Americas Securities LLC grew its holdings in shares of LENZ Therapeutics by 20.7% during the fourth quarter. SG Americas Securities LLC now owns 5,458 shares of the company’s stock worth $158,000 after buying an additional 935 shares in the last quarter. 54.32% of the stock is owned by hedge funds and other institutional investors.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.